Photo taken from Vivek Subbiah/LinkedIn
Nov 22, 2023, 02:38
Vivek Subbiah: When JAMA publishes a phase 1 study, it will be a practice-changing study in the future- Lepodisiran
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“When JAMA publishes a phase 1 study, it will be a practice-changing study in the future- Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a). In this phase 1 study of 48 participants with elevated lipoprotein(a) levels, lepodisiran was well tolerated and produced dose-dependent, long-duration reductions in serum lipoprotein(a) concentrations.”
For details click here.
Source: Vivek Subbiah/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 06:51
Nov 20, 2024, 01:07
Nov 20, 2024, 01:00
Nov 20, 2024, 00:40
Nov 20, 2024, 00:31
Nov 20, 2024, 00:29